

Index

Note: Page numbers followed by “*f*” and “*t*” refer to figures and tables, respectively.

A

Acute mood episodes, biomarkers for lithium efficacy in, 299–305, 300*t*, 305*t*
 Adaptive immune system, 194
 Adenylate cyclase 2 (ADCY2) gene, 295–296
 ADRA2A, 492
 ADRB3, 492
 Adrenocorticotrophic hormone (ACTH), 314, 414
 Affective cognition, 260–261
 Aging mechanism
 altered intercellular communication, 160–161
 cellular senescence, 157–158
 DNA damage, 158–159
 epigenetic alterations, 158–159
 genomic instability, 158–159
 hallmarks of biological aging, 162*t*
 mitochondria dysfunction, 159–160
 telomere attrition in, 157–158
 Allostatic load, 324
 α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPA*s*), 227
 Alpha-diversity in BD, 416–417
 Alzheimer’s disease (AD), 334–335, 414–415
 “Amoeboid” morphology, 196
 Amphetamines, 66
 Amplitude of low-frequency fluctuation (ALFF), 24
 Animal models
 of depression, 72–75
 of mania, 65–70
 mitochondrial dysfunction, 147–149
 of psychiatric disorders, 64
Ank3 gene, 69, 215–217
ANT1 gene, 145
 Anterior cingulate cortex (ACC), 83, 86, 97

Antibipolar drugs, action mechanisms of, 150–151
 Antibody-based methods, 460
 Antidepressants, 492
 Aryl hydrocarbon receptor nuclear translocator-like (ARNTL) gene, 296–297
Atp1a3 gene, 69
 Attentional bias, 23
 Atypical antipsychotics, 492
 Auditory steady state response (ASSR), 226
 Autonomic nervous system (ANS), 410

B

Base excision repair (BER), 364, 369–371
Bdnf gene, 75
 Betadiversity in BD, 417
 Big data, 115
 Biological processes and pathways, 475
 Biomarker(s), 82, 459
 in bipolar disorder, 41–42
 current limitations, 9–10
 future directions in, 11–12
 categories, 5–9, 6*f*
 diagnosis/trait, 6–7
 prognosis, 8
 risk, 5–6
 stage, 7–8
 state/acuteity, 7
 treatment response, 8–9
 definition of, 2–5
 of lithium efficacy in bipolar disorders
 acute mood episodes, biomarkers for lithium efficacy in, 299–305
 lithium prophylaxis efficacy, biomarkers of, 294–299
 lithium’s efficacy, 293–294
 process of discovering and validating, 2, 3*f*
 rationale for, in bipolar disorder, 2–5, 4*f*
 Black bile, 191–192

- Blood–brain barrier (BBB), 405–406, 412
- Brain-derived neurotrophic factor (BDNF), 419–420, 441–443
- Brain-derived neurotrophic factor (BDNF), 7, 277, 281–285, 295, 304, 337–338, 492

C

- Cancer research and bipolar disorder, 373–374
- CACNA1C, 490–491
- Calcium signaling, 331–333
 - in cells, 143f
- Cambridge Neuropsychological Test
 - Automated Battery, 258
- cAMP response element-binding (CREB), 442
- Canadian Rapid Treatment Center of Excellence, 239–240
- Candidate gene, 296
- Cannabinoid receptor 1 (*Cb1*) gene, 75
- Capillary electrophoresis time-of-flight mass spectrometry (CETOFMS), 43
- Cellular senescence, 157–158
- Cellular studies, 440–443
 - glycogen synthase kinase-3 β , 442–443
 - mitochondrial-mediated pathway, 440–441
 - neurotrophic factors and associated pathway, 441–442
- Central nervous system (CNS), 385–387, 405–406, 410–413
- Cerebrospinal fluid, mitochondrial dysfunction, 144
- C–G dinucleotides (CpG), 267–268, 277
- Cho, 100–101
- Choline, 100–101, 103f
- Chronic mild stress, 73, 74t
- Chronic progressive external ophthalmoplegia (CPEO), 145
- Chronic restraint stress, 73–74
- Circadian biomarkers of bipolar disorder, 349–351
 - future research, 355–356
 - light sensitivity, 351
 - objectively measured sleep, activity/
 - circadian rhythms, 351–354
 - circadian rhythms, 353–354
 - motor activity, 352–353
 - sleep, 352
 - endophenotypes for BD, 354–355
 - sleep characteristics, 349–351
- Circadian locomotor output cycles protein kaput (CLOCK), 68

- Classical bowel toxemia theory, 385
- Clinical Pharmacogenetics Implementation Consortium (CPIC), 489–490
- Clock, 295–296
- Clock19*, 215–216
- Cognitive dysfunctions, 254–255
- Cognitive impairment, 253–254
- Cognitive inhibition, 23
- Coheritability, 130
- Collapsin response mediator protein-2 (CRMP2), 295
- Common variant heritability, 130
- ConLiGen group, 297–298
- Corticosteroid-binding globulin (CBG), 320–321
- Corticosterone, 74
- Corticotrophin-releasing hormone (CRH), 314, 318–319, 321–322
- C-reactive protein (CRP), 7
- Creatine, 101, 103f
- Crohn's disease, 385, 404
- Cyberball game, 22
- CYP1A2, 488
- CYP2C9, 490
- CYP2C19, 487, 489–490
- CYP2D6, 487–490
- CYP3A4, 488
- CYP3A5, 488
- Cytochrome P450 (CYP), 486–487
- Cytokines, pro-inflammatory, 161

D

- Damage-associated molecular patterns (DAMPs), 175–176
- Dbp* gene, 70
- Default mode network (DMN), 445–446
- Deficient social cognition, 21–23
- Deoxyribonucleic acid (DNA), 267–269
- Depression
 - animal models of, 72–75
 - environmental models, 72–74
 - chronic mild stress, 73, 74t
 - chronic restraint stress, 73–74
 - maternal deprivation/separation, 72–73
 - genetic models of, 75
 - Bdnf* and *Trkb* genes, 75
 - Cb1* gene, 75
 - Tph2* gene, 75
 - pharmacological models of, 74
 - corticosterone, 74
 - surgical model of, 74–75
 - olfactory bulbectomy, 74–75

Depressive-like behavior assessment, in
 animals, 76–77, 78*t*
 forced swimming test, 76
 tail suspension test, 76
 sweet food consumption test, 76–77
 splash test, 77
 Dexamethasone suppression test (DST),
 320–321, 322*t*
 Diacylglycerol (DAG), 333–335
 Diffusion tensor imaging (DTI), 26, 83–84,
 444–445
 DNA damage and affective states, 367–369
 DNA damage and repair mechanisms,
 363–364
 DNA damage, biological aging, 158–159
 DNA damage markers, 364–366, 365*f*
 DNA damage/repair mechanisms, 363–364
 DNA methylation, 268–269, 279*t*, 284*t*
 analysis, sample source for, 269
 and animal and preclinical model studies
 of, 283–285
 and bipolar disorder diagnosis, 270–278
 global methylation studies, 270
 whole-genome analyses, 270–276, 274*t*
 gene-specific analyses, 271*t*, 276–278
 measurement of, 268–269
 role in bipolar disorder, 269–270
 and treatment response in bipolar disorder,
 278–283
 gene-specific studies, 281–283
 global methylation, 278–281
 whole-genome analyses, 281
 DNA repair markers, 369–372
 Dopamine transporter (DAT), 68
 Dorsal PFC (DPFC), 257–258
 DRD2, 492
 Drug discovery research, mitochondrial
 dysfunction, 149
 Drug metabolism, 486–490
 Drugs development targeting gsk-3 β ,
 447–449
 DSM-5 classification, 167–168
 Dysbiosis, 403–404

E

8-oxo-dG, quantification of, 366–367
 Electroencephalography (EEG), 63, 223–226,
 225*t*
 Endophenotype approach, 255–257, 354–355
 Enteric nervous system (ENS), 410–412
 Environmental animal models, 64–66
 paradoxical sleep deprivation, 65–66

Environmental models of depression, 72–74
 chronic mild stress, 73, 74*t*
 chronic restraint stress, 73–74
 maternal deprivation/separation, 72–73
 Enzyme-linked immunosorbent assay
 (ELISA), 460
 Epigenetic alterations, biological aging,
 158–159
 Epstein—Barr virus, 295
 ERK/MAPK pathway, 441–442
 Excellent lithium responders, 294–295
 Extensive or normal metabolizers, 485–486

F

Fecal microbiota transplantation (FMT),
 414–415, 419, 421–422
 Fever therapy, 191–192
 Fine mapping, 129–130
 5-HTTLPR, 492
 Food and Drug Administration (FDA),
 486–487, 491
 Forced swimming test, 76
 Functional magnetic resonance imaging
 (fMRI), 63

G

Gamma-aminobutyric acid (GABA), 96–98,
 99*f*, 388–389
 Gas chromatography-mass spectroscopy (GC-
 MS), 40–41
 Gastrointestinal dysfunction
 and inflammation, 404, 405*f*
 in psychiatric disorders, 404–406
 Gastrointestinal tract, 385–386
Gclm, 215–217
 Gene-specific analyses, 276–278, 281–283
 Genetic factors, 351
 Genetic models, of depression, 75
Bdnf and *Trkb* genes, 75
 cannabinoid receptor 1 (*Cb1*) gene, 75
 tryptophan hydroxylase 2 (*Tph2*) gene, 75
 Genetic models, of mania, 64, 68–70
Ank3 gene, 69
Atp1a3 gene, 69
Clock gene, 68
Dat gene, 68
Dbp gene, 70
Grik2 gene, 69
Gsk-3 gene, 69–70
Shank3 gene, 68–69
 Genetics, mitochondrial dysfunction,
 144–145

Genome-wide association studies (GWAS),
 5–6, 126–127, 231, 296–298, 351,
 461–472, 490–491
 challenges and opportunities for next era,
 134–135
 common variant heritability and
 coheritability, 130
 fine mapping, 129–130
 heritability and family studies, 126
 Manhattan plot, 128*f*
 missing heritability, 133
 pharmacogenetics, 133–134
 polygenic risk scores, 131–133, 132*f*
 recent results of, 127–129
 Genomic instability, biological aging,
 158–159
 Germ-free (GF) animal studies, 413–414
 Germ-free mice (GFM), 389–390
 Global methylation, 270, 278–281
 Glucocorticoid receptors (GRs), 314–315
GluD1, 215–217
 Glutamate decarboxylase-like protein
 (GADL1), 296–297
 Glutamate receptor-based biomarkers,
 227–232, 228*t*
 ionotropic, 227–231
 metabotropic, 231–232
 Glutamate, 96–98
 Glutamate-based dysfunction
 clinical, 219–232
 electroencephalography, 223–226, 225*t*
 glutamate receptor-based biomarkers,
 227–232
 magnetic resonance spectroscopy,
 219–223, 221*t*
 positron emission tomography, 226–227
 preclinical, 215–219
 treatment, 233–241, 234*t*
 ketamine, 237–241
 lamotrigine, 233–236
 riluzole, 236–237
 Glutamatergic hyperactivity, 96–98
 Glutamine, 96–98
 Glycogen synthase kinase-3 β , 442–443
 GNB3, 492
 Graph theory model, 24
Grik2 gene, 69, 215–217
Gsk-3 gene, 69–70
 GSK3- β /Wnt pathways, 335–337

H

Hamilton Depression Rating Scale, 233–236

Harvard Brain Bank, 146
 Hayling Sentence Completion Task (HSCT),
 257–258
 Healthy controls (HC), 258–261, 472–474
 High-dimensionality (H-D), 476
 Hippocampus, 86–87
 HLA-B*15:02 allele, 491
 Homocysteine, 7
 Homologous recombination, 364
 Hormonal mechanisms, 350
 Hormones, 160
 HTR2C, 492
 Human genome, 126–127, 485
 Human gut microbiota, 386–387, 406–410
 Human studies, 415–416
 Humoral theory, 191
 Humors, 191
 Hydrophilic interaction liquid
 chromatography-high resolution mass
 spectrometry (HILIC-HRMS), 43
 Hypothalamus—pituitary—adrenal (HPA)
 axis, 202, 203*f*, 313–316, 315*f*,
 322–325, 385–386, 410, 412
 dysregulation, 176–177

I

Iatrogenic poor phenotype, 488–489
 Iba1-IR microglia/macrophages, 28–29
 Illumina HumanMethylation, 268–269
 Immune system, 192–194, 193*f*
 Immunoassay methods, 460
 Independent component analyses (ICA), 24
 Induced pluripotent stem cells (iPSCs), 295
 Ingenuity pathway analysis (IPA), 461–472,
 475
 INSIG2, 492
 Insulin signaling, 176–177
 Insulin-like growth factor binding protein
 (IGFBP3 and IGFBP5), 473–474
 Intercellular communication, 160–161
 Intermediate metabolizers, 485–486
 Intermediate phenotype, 255–256
 International Society for Bipolar Disorders
 Task Force, 240–241
 Intracellular signaling abnormalities, 102–104
 myo-inositol, 102–104, 105*f*
 Intracellular signaling cascades
 brain-derived neurotrophic factor, 337–338
 calcium signaling, 331–333
 diacylglycerol/protein kinase C pathways,
 333–335
 GSK3- β and Wnt pathways, 335–337

mitochondrial dysfunction, 338–339
 iPS cell model, mitochondrial dysfunction,
 149–150
 Irritable bowel disease (IBD), 404, 415–416,
 419–420
 Irritable bowel syndrome (IBS), 404–405,
 412
 Isobaric tags for relative and absolute
 quantitation (iTRAQ)

K

Ketamine, 237–241
 Kindling theory, 169
 defined, 67–68
 KIT-ligand (KITLG), 473–474

L

Lactate, 101–102, 103*f*
 Lamotrigine, 233–236
 carbamazepine, 491
 LARS2 (mitochondrial leucyl-tRNA
 synthetase), 146–147
 Lateral hypothalamic kindling model,
 67–68
 Light sensitivity, 351
 Linkage disequilibrium (LD), 127
 Lipopolysaccharide (LPS), 405–406
 Liquid chromatography-mass spectroscopy
 (LC-MS), 40–41, 461
 Lithium (Li), 491
 for BD treatment, 63
 efficacy, 293–294
 Lithium prophylaxis efficacy, biomarkers of,
 294–299
 Lymphocytes, 197

M

Machine learning model, 115–116, 116*t*, 117*f*
 for suicidality prediction, 119
 supervised learning, 121
 for treatment selection, 120
 unsupervised learning, 121
 Macrophages, 28–29
 Magnetic resonance imaging (MRI),
 444–445, 447
 Magnetic resonance spectroscopy (MRS),
 glutamate-based dysfunction,
 219–223, 221*t*
 brain regions involved in cognitive and
 affective regulation, 104–106, 106*t*
 metabolite abnormalities in, 96–104
 glutamatergic hyperactivity, 96–98

intracellular signaling abnormalities,
 102–104
 mitochondrial dysfunction and neuronal
 alterations, 98–102
 proton Mrs, 95–96
 Magnetoencephalography (MEG), 63
 Major depressive disorder (MDD), 22,
 200–201, 350–353, 355, 414–417,
 461, 473–475, 485, 488–490
 Malaria therapy, 191–192
 Mania, animal models of, 65–70
 environmental models, 65–66
 genetic models, 68–70
 pharmacological models, 66–67
 surgical model, 67–68
 Mania-like behavior assessment, in animals,
 70–72
 delayed discounting task, 71
 open-field test, 70–71
 hyperactivity, 70
 risk-taking behavior, 71
 sexual behavior, 71
 stereotypy, 70
 resident—intruder test, 71
 sexual behavior test, 72
 Mass spectrometry (MS), 460–461
 Maternal deprivation/separation, 72–73
 Matrix-assisted laser desorption/ionization-
 time of flight (MALDI-TOF/TOF),
 461
 MC4R, 492
 Metabolic fingerprinting, 40
 Metabolite abnormalities, in BD, 96–104
 glutamatergic hyperactivity, 96–98
 intracellular signaling abnormalities,
 102–104
 myo-inositol, 102–104, 105*f*
 mitochondrial dysfunction and neuronal
 alterations, 98–102
 choline, 100–101, 103*f*
 creatine, 101, 103*f*
 lactate, 101–102, 103*f*
 N-acetyl-aspartate, 98–100, 103*f*
 Metabolomics
 in bipolar disorder, 42–51
 blood/urine metabolomic analyses,
 44–49, 45*t*, 50*f*
 brain tissue/cerebrospinal fluid
 metabolomics analysis, 42–44
 future directions of, 51–53
 defined, 39
 in psychiatric disorders, 39–41

Metabolomics (*Continued*)

- targeted, 39–40
- untargeted, 39–40

Methylation DNA immunoprecipitation (MeDIP), 270–276

Microbiome and bipolar disorder

- microbiota-gut-brain axis, 385–396
 - and mental health, 388–389
 - biomarker of treatment response in, 395–396
 - consequences of, 387–388
 - diagnostic biomarker for, 391–394
 - differential diagnosis biomarker for, 394–395
 - mood state biomarker for, 394
 - tools, 389–391

Microbiome-gut-brain (MGB) axis, 410–413, 411f, 416

Microbiota-gut-brain axis (MGBA), 385–396, 387f, 390f

Microglia, 28–29

Microglial activation, 196–197

Micro-RNA (miR), 298

Mineralocorticoid receptors (MRs), 314–315

- glucocorticoid receptors, 316–320, 318f, 318t, 319t

Mismatch negativity (MMN), 224–226

Mismatch repair, 364

Missing heritability, 133

Mitochondria dysfunction, 159–160

Mitochondrial DNA (mtDNA), 141–142

- damage and repair, 372–373

Mitochondrial dysfunction

- action mechanisms of antibipolar drugs, 150–151

- animal models, 147–149

- cellular models, 142–144

- cerebrospinal fluid, 144

- drug discovery research, 149

- genetics, 144–145

- iPS cell model, 149–150

- molecular and cellular pathogenesis in PVT, 150–151

- neural circuits around PVT, 151

- postmortem brains, 146–147

- proposal of mitochondrial hypothesis, 141–142

Mitochondrial dysfunction and neuronal

- alterations, 98–102

- choline, 100–101, 103f

- creatine, 101, 103f

- lactate, 101–102, 103f

N-acetyl-aspartate, 98–100, 103f

Mitochondrial permeability transition pore (mPTP), 149

Mitochondrial-mediated pathway, 440–441

Monoamine dysregulation, 66

Monocyte to lymphocyte ratio (MLR), 197–198

Montgomery Åsberg Depression Rating Scale, 233–236

Motor activity, 352–353

Multisystem inflammatory disease, 403–404

Myo-inositol, 102–104, 105f

N*N*-acetyl-aspartate (NAA), 98–100

The National Center for Biotechnology Information (NCBI), 485–486

Near infrared spectroscopy (NIRS), 63

Neuregulin (NRG1) gene, 295–296

Neurocognitive endophenotypes, 257–263

- affective cognition, 260–261

- cognitive dysfunctions, 253–255

- endophenotypes, concept of, 255–257

- limitations of, 261–263

Neurocognitive studies, of suicidal behavior, 20–27

- cognitive processes, 23

- deficient social cognition, 21–23

- neuroimaging studies for classification, 26

- pharmacological neuroimaging studies, 25

- resting state neuroimaging studies, 24–25

- risky decision-making, 20–21

- structural neuroimaging studies, 25–26

- tentative neuroanatomical summary of suicidal acts, 26–27

Neurodegeneration vs. neuroplasticity, 173–174

Neuroendocrine and stress pathways

- hypothalamus—pituitary—adrenal axis, 314–316

- mineralocorticoid receptors/glucocorticoid receptors, 316–320

- neuroendocrine function test, 320–323

- psychoneuroendocrine progression of, 324t

- steroid hormones, 316

- stress, 324–325

Neuroendocrine function test, 320–323

Neuroimaging markers, in psychiatry, 82

Neuroimaging studies, 444–447

- diffusion tensor imaging, 444–445

- drugs development targeting gsk-3 β , 447–449

- neuroinflammation, 446–447
 - resting-state functional magnetic resonance imaging, 445–446
 - structural magnetic resonance imaging, 444
 - Neuroimmune pathways
 - evidence of immune dysfunction, 194–200
 - circulating levels of immune markers, 199–200
 - clinical evidence, 195–196
 - genetic evidence, 194–195
 - immune cells (total count, phenotype, and function), 197–199
 - inflammatory markers in central nervous system, 196–197
 - microglial activation, 196–197
 - immune-based strategies, 204–205
 - immune (cerebrospinal fluid and blood)
 - markers of diagnosis, 200–201
 - immune markers as predictors, 205
 - immune system, 192–194, 193*f*
 - integrating immune dysfunction with of bipolar disorder, 201–204
 - Neuroinflammation, 446–447
 - Neuroprogression, in bipolar disorder
 - biological basis of, 171–177
 - hypothalamic—pituitary—adrenal axis dysregulation, 176–177
 - insulin signaling, 176–177
 - molecular changes associated with progression of illness, 175–176
 - neuroanatomical changes, 171–173
 - neurodegeneration vs. neuroplasticity, 173–174
 - clinical evidence of, 169–171
 - clinical features, 169–170
 - functioning, 171
 - neurocognitive changes, 170–171
 - evidence of, 168
 - future perspectives, 177–178
 - Neuropsychiatric disorders, microbiome-gut-brain-axis findings in, 413–415
 - Neurotrophic factors/associated pathway, 441–442
 - Neurotrophins, 337
 - Neutrophil to lymphocyte ratio (NLR), 197–198
 - Neutrophils, 197
 - NIMH Family Study, 353–355, 355*t*
 - N*-methyl-D-aspartate receptors (NMDARs), 196, 227
 - Nonhomologous end-joining (NHEJ), 364
 - Noninvasive functional imaging technologies, 63
 - Nonsteroidal antiinflammatory drugs, 204
 - Nuclear magnetic resonance (NMR) spectroscopy, 40–41
 - Nucleotide excision repair (NER), 364
- ## O
- O-desmethylvenlafaxine, 489
 - Olfactory bulbectomy, 74–75
 - “OMICS”, 475–476
 - Operational taxonomic unit (OTU), 410
 - Orbitofrontal cortex, 86
 - Ouabain (OUA), 67
 - Oxidative stress, 362–363
- ## P
- Paradoxical sleep deprivation, 65–66
 - Paraventricular thalamic nucleus (PVT), 147–148, 148*f*
 - molecular and cellular pathogenesis in, 150–151
 - neural circuits around, 151
 - Parkinson’s disease (PD), 147–148, 414–415
 - Peripheral blood, proteome characterization of, 461–472
 - Pharmacodynamics, 133–134
 - Pharmacogenetics, 133–134
 - Pharmacogenomics
 - of drugs commonly used in bipolar disorder, 490–492
 - antidepressants, 492
 - atypical antipsychotics, 492
 - lamotrigine and carbamazepine, 491
 - lithium, 491
 - valproic acid, 490–491
 - and genetic variation, 485–486
 - pharmacokinetic, 486–490
 - CYP2C19, 489–490
 - CYP2C9, 490
 - CYP2D6, 487–489
 - Pharmacokinetic, 133–134, 486–490
 - Pharmacological animal models, 64
 - amphetamines, 66
 - ouabain, 67
 - Pharmacological models, of depression, 74
 - corticosterone, 74
 - Pharmacological neuroimaging studies, 25
 - Pharmacometabolomics of bipolar disorder, 49–51
 - Plasticity, 439–440, 440*f*
 - Platelet to lymphocyte ratio (PLR), 197–198

Pneumoencephalography, 81–82
 Polygenic risk scores (PRS), 131–133, 132*f*
 Polymorphism XBP1—116 C/G, 490–491
 Poor metabolizers, 485–486
 Positron emission tomography (PET), 22–23, 63, 447
 glutamate-based dysfunction, 226–227
 Postmortem brain research, exploring cellular/
 molecular roots of suicide, 27–30
 evidence of activated microglia/
 macrophages, 28–29
 inflammation/cognition, 30
 molecular evidence of increased
 inflammation in depression/suicide, 29
 Postmortem brains, mitochondrial
 dysfunction, 146–147
 Prebiotics, 420–421
 Precision Medicine Initiative, 483
 Precision psychiatry, 484*f*
 in bipolar disorder
 diagnosis and differential diagnosis,
 116–118
 prognosis prediction, 118–119
 suicidality prediction, 119
 treatment selection, 120–121
 supervised/unsupervised learning, 121
 Prednisolone, 322
 Prednisolone suppression test (PST), 322, 322*t*
 Prefrontal cortex (PFC), 440–441, 444
 Prognostic biomarkers, 8
 Protein kinase C (PKC), 333–335, 337
 Proteome, 459–460
 Proteomic biomarkers for bipolar disorder
 biological processes and pathways, 475
 blood serum and plasma-based
 investigations of, 462*t*
 current status, 472–473
 differentially abundant proteins, 473–475
 “OMICS,” future of, 475–476
 peripheral blood, proteome characterization
 of, 461–472, 462*t*
 proteomic techniques, development of,
 460–461
 Proton magnetic resonance spectroscopy (¹H-
 Mrs), 95–96
 Psychiatric disorders, gastrointestinal
 dysfunction in, 404–406
 The Psychiatric Genomics Consortium, 8

Q

Quantitative Insights Into Microbial Ecology
 (QIIME), 390–391

Quantitative trait loci (QTL) mapping studies,
 129–130

R

Radioimmunoassay (RIA), 320–321
 Rapid and ultrarapid metabolizers, 485–486
 Rapid eye movement (REM) sleep, 224–226
 Receiver operative characteristic area under
 the curve (ROC-AUC), 473
 Red blood cells (RBC), 331–332
 Reducing the noise, 256–257
 Refining the genetic signal, 256–257
 Renin—angiotensin—aldosterone system
 (RAAS), 313
 Resting state neuroimaging studies, 24–25
 Resting-state functional magnetic resonance
 imaging (rs-fMRI), 445–446
 Ribonucleic acid-based (RNA), 267–268
 Riluzole, 236–237
 Risk biomarkers, 5–6
 Risky decision-making, in suicide attempters,
 20–21
 Rodent sexual behavior test, 72

S

Schizophrenia (SZ), 200–201, 461, 473, 475
 vs. bipolar disorder, 84–85
 SCN2A, 490–491
 Search engines, 460–461
 Second-generation antipsychotics (SGA), 50
 Selective serotonin reuptake inhibitors
 (SSRIs), 489–490
 Senator, Hermann, 385
Shank3, 68–69, 215–217
 Short-chain fatty acids (SCFAs), 412–413,
 420–421
 Shotgun proteomics, 460–461
 Single-nucleotide polymorphisms (SNPs), 8,
 295–298, 485–486
 Single-photon emission computed tomography
 (SPECT), 22–23
 16S rRNA gene, 390–391
 SLC6A4, 492
 Sleep, 352
 characteristics, 349–351
 Sleep-wake cycle, 350
 SNAP25, 492
 Sodium, potassium-activated adenosine
 triphosphatase (Na/K-ATPase), 67
 Splash test, 77
 Stage biomarkers, 7–8
 State/acuity biomarker, 7

Steroid hormones, 316
 Structural magnetic resonance imaging, 444
 Structural neuroimaging markers, in bipolar disorder, 82–84
 bipolar disorder
 vs. schizophrenia, 84–85
 vs. unipolar depression, 85–87
 biomarker, 82
 diffusion tensor imaging, 83–84
 existing literature, overview of, 83
 in high-risk populations, 87–88
 neuroimaging markers, in psychiatry, 82
 as tool to improve diagnostic accuracy, 84–87
 Subclinical trait, 255–256
 Suicidality, 24–25
 Suicide attempters, risky decision-making in, 20–21
 Supervised learning, 121
 Surgical models
 of depression, 74–75
 olfactory bulbectomy, 74–75
 of mania, 64
 lateral hypothalamic kindling, 67–68
 Sweet food consumption test, 76–77
 Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study, 171, 492

T

Tail suspension test, 76
 Tandem mass tag (TMT), 472–473
 Targeted proteomics, 461

Taxonomic level analyses, 417–418
 Telomere attrition, 157–158
 Thyroid-stimulating hormone (TSH), 295
 Timeless circadian clock (TIM) gene, 296–297
 Toll-like receptors (TLRs), 175–176
 Translocation, 404–406
 Treatment, 419–422
 Treatment response biomarker, 8–9
Trkb gene, 75
 Tryptophan hydroxylase 2 (*Tph2*) gene, 75
 Tumor necrosis factor alpha (TNF- α), 412–413

U

Unipolar depression
 vs. bipolar disorder, 85–87
 Unsupervised learning, 121

V

Valproic acid (VPA), 490–491
 Vasopressin (AVP), 314, 318–319
 Ventral prefrontal cortex (VPFC), 257–258
 Vulnerability marker, 255–256

W

Whole-genome analyses, 270–276, 281
 Wisconsin Card Sorting Test, 257–258

Y

Young Mania Rating Scale (YMRS), 240–241